Please provide your email address to receive an email when new articles are posted on . Researchers produced an algorithm to standardize virtual myasthenia gravis assessments. More efforts are needed ...

Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...

In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab ...

The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...

How Do Vyvgart & Vyvgart Hytrulo Work in gMG? gMG is an autoimmune disease where the immune system mistakenly damages the connections between your nerves and muscles. This weakens your muscles and ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Ocular MG is a milder form of generalized MG, with lower AChR titers and less aggressive treatment needs. AChR titers above 100 nmol/L at diagnosis predict progression from ocular to generalized MG.

The FDA in April 2025 approved nipocalimab (Imaavy) as a treatment for people living with generalized myasthenia gravis (gMG). Specifically, nipocalimab is for people with gMG who are 12 and older and ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...